The emergence of resistant mutations within the ABL kinase domain of BCR-ABL1 is a well-established mechanism of TKI resistance in CML and Philadelphia-chromosome-positive ALL (Ph-pos ALL)30. This evidence concerns the gene BCR and acute lymphoblastic leukemia.